Press Release Archives
CRISPR Therapeutics AG
CRISPR Therapeutics AG develops gene-based medicines for patients with serious diseases. Its therapeutic molecular level using the breakthrough genome-editing technology called CRISPR-Cas9. The company was founded by Rodger Novak, Emmanuelle Charpentier and Shaun Patrick Foy in 2014 and is headquartered in Basel, Switzerland.

CRISPR Therapeutics AG Press Releases

Press Archives

CRISPR Therapeutics AG

Press Archives

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results

Oct 28th 2019

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

May 1st 2019

May 1, 2019 ZUG, Switzerland and CAMBRIDGE, Mass., May 01, 2019 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating tr

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results

Apr 29th 2019

April 29, 2019 -Enrollment ongoing in Phase 1/2 clinical trials of CTX001™ for patients with severe hemoglobinopathies- -IND and CTA approved for CT

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia

Apr 16th 2019

April 16, 2019 ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, April 16, 2019 -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorpor

CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2019 Annual Meeting

Feb 27th 2019

February 27, 2019 ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 27, 2019 -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on crea

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

Feb 25th 2019

February 25, 2019 -First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta thalassemia- -First patient enrolled in a Phase

CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001

Feb 25th 2019

February 25, 2019 -First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta thalassemia- -First patient enrolled in a Phase

CRISPR Therapeutics Proposes New Members to the Board of Directors

Feb 21st 2019

February 21, 2019 ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 21, 2019 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on crea

CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement

Feb 19th 2019

--Expansion of Collaboration to Focus on the Development of Novel Capsids for Additional Applications--

CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies

Jan 22nd 2019

January 22, 2019 CAMBRIDGE, Mass. and BOSTON and BERLIN, Jan. 22, 2019 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease

Jan 4th 2019

January 4, 2019 ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Jan. 04, 2019 -- CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Inco

CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology

Nov 9th 2018

November 9, 2018 --CRISPR Therapeutics Gains Additional Rights to MaxCyte’s Cell Engineering Technology to Develop CRISPR/Cas9-Based Cell Therapies